BRENTWOOD, Tenn. / Aug 25, 2025 / Business Wire / Ardent Health (NYSE: ARDT), a leading provider of healthcare in growing mid-sized urban communities across the U.S., today announced that members of the Company’s management team will participate in the following upcoming investor conferences:
A live audio webcast of these presentations will be available in the Investor Relations section of the Company’s website, at https://ir.ardenthealth.com. A replay will be available on the same webpage after the webcast conclusion.
In conjunction with these conferences, the Ardent Health management team will be available to participate in one-on-one meetings with investors registered to attend each conference. For more information, please contact your sales representative at the host firm, or Dave Styblo, Ardent Health’s senior vice president of investor relations, at This email address is being protected from spambots. You need JavaScript enabled to view it..
About Ardent Health
Ardent Health (NYSE: ARDT) is a leading provider of healthcare in growing mid-sized urban communities across the U.S. With a focus on people and investments in innovative services and technologies, Ardent is passionate about making healthcare better and easier to access. Through its subsidiaries, the Company delivers care through a system of 30 acute care hospitals and approximately 280 sites of care with over 1,800 employed and affiliated providers across six states. For more information, please visit ardenthealth.com.
Last Trade: | US$12.69 |
Daily Change: | 0.16 1.28 |
Daily Volume: | 166,981 |
Market Cap: | US$1.820B |
August 05, 2025 May 06, 2025 March 31, 2025 |
Amneal Pharmaceuticals is a fully-integrated essential medicines company. We make healthy possible through the development, manufacturing, and distribution of generic and specialty pharmaceuticals. The Company has a diverse portfolio of over 250 products in its Generics segment and is expanding across...
CLICK TO LEARN MOREAstria Therapeutics is a biopharmaceutical company, and our mission is to bring life-changing therapies to patients and families affected by rare and niche allergic and immunological diseases. Our lead program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in clinical development...
CLICK TO LEARN MOREEnd of content
No more pages to load